Simultaneous departure of three directors without named replacements at a micro-cap biotech suggests potential board instability or a strategic pivot. Monitor for any subsequent 8-Ks naming new directors, filings on Nasdaq listing compliance (as board size may fall below minimum requirements), and the upcoming 10-Q for the quarter ending June 30, 2026, which should include the separation agreements as exhibits.
Price Chart
Executive Summary
Three board directors (Stephen Brady, Michael Raab, Christine Pellizzari) resigned from Tempest Therapeutics' board effective May 22, 2026. The company states these resignations were not due to any disagreement with operations or policies. No replacements were named, and departing directors waived accrued retainer fees under separation agreements while retaining existing stock options and indemnification rights. For a micro-cap biotech ($27M market cap), the simultaneous departure of a quarter-plus of the board is a governance red flag.
Key Facts
- Three directors resigned simultaneously: Stephen Brady, Michael Raab, and Christine Pellizzari
- Resignations effective May 22, 2026
- No replacements have been named
- Company states no disagreement with operations, policies, or practices
- Directors waived all accrued/unpaid retainer fees under separation agreements
- Outstanding stock options and share ownership rights unaffected; indemnification agreements remain for six years
- President and CEO Matthew Angel remains as sole C-suite signatory
- Market cap: $27M (Nasdaq-listed micro-cap biotech)
Financial Impact
No direct financial figures in filing; retainer fee waiver is trivial for a $27M company
Risk Factors
- Nasdaq may require a minimum board size; three departures simultaneously could risk non-compliance
- No replacements named suggests difficulty attracting qualified directors or pending corporate action
- Potential loss of institutional confidence in governance for a development-stage biotech reliant on partnerships and financing
- Waiver of fees could signal cash constraints at the company
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-237150 |
| Document: 0001193125-26-237150-index-headers.html | 0001193125-26-237150 |
| Document: 0001193125-26-237150-index.html | 0001193125-26-237150 |
| Document: 0001193125-26-237150.txt | 0001193125-26-237150 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | DEF 14A | $0.5102 | awaiting T+20 | — | $0.5107 (−0.10%) |
Oct 20, 2026 7d ago | DEFA14A | $0.5282 | awaiting T+20 | — | $0.5107 (−3.31%) |
Oct 20, 2026 7d ago | 8-K | $0.5282 | awaiting T+20 | — | $0.5107 (−3.31%) |
Oct 19, 2026 8d ago | 8-K | $0.5762 | awaiting T+20 | — | $0.5107 (−11.37%) |
Oct 2, 2026 25d ago | EFFECT | $0.8112 | awaiting T+20 | — | $0.5107 (+37.04%) |
Sep 25, 2026 4w ago | S-3 | $0.8316 $0.5102 | ▲ +38.65% | ▲ +38.62% | $0.5107 (+38.59%) |
Sep 17, 2026 5w ago | 8-K | $0.9680 $0.6240 | ▼ −35.54% | ▼ −35.74% | $0.5107 (−47.24%) |
Sep 16, 2026 5w ago | DEFA14A | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5107 (−42.94%) |
Sep 16, 2026 5w ago | 8-K | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5107 (−42.94%) |
Sep 11, 2026 6w ago | Press Release | $0.8117 $0.7601 | ▲ +6.36% | ▲ +8.23% | $0.5107 (+37.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers